Compound Overview and Scientific Significance

3-Bromo-6-fluoroimidazo[1,2-a]pyridine (Aladdin SKU: B732541) belongs to the imidazo[1,2-a]pyridine family of fused bicyclic nitrogen heterocycles. The imidazo[1,2-a]pyridine scaffold is recognized as a privileged structure in medicinal chemistry due to its drug-like physicochemical properties, metabolic stability relative to monocyclic pyridines, and its presence in numerous bioactive compounds and approved pharmaceuticals.

The C-3 bromine substituent provides a handle for a wide range of transition-metal-catalyzed reactions, including Suzuki–Miyaura, Negishi, Sonogashira, and Buchwald–Hartwig couplings, enabling efficient library synthesis and lead optimization. The C-6 fluorine atom modulates the electron density of the ring system, influences lipophilicity (logP), enhances metabolic stability by blocking cytochrome P450-mediated oxidation at that position, and can improve membrane permeability—all highly desirable properties in drug candidates.

Together, these two halogen substituents make 3-Bromo-6-fluoroimidazo[1,2-a]pyridine an exceptionally useful dual-functional building block for the construction of complex heterocyclic architectures relevant to kinase inhibitor programs, CNS drug discovery, anti-infective research, and other therapeutic areas.

Materials and Safety Requirements

Required Materials:

• 3-Bromo-6-fluoroimidazo[1,2-a]pyridine (Aladdin B732541)
• Appropriate anhydrous solvents (e.g., DMF, DMSO, THF, dioxane) depending on the intended reaction
• Transition-metal catalyst and ligand system (for cross-coupling applications)
• Analytical balance (milligram sensitivity)
• Inert atmosphere apparatus (Schlenk line or glovebox, recommended for air/moisture-sensitive reactions)
• Standard personal protective equipment (PPE)

Safety Precautions:

• Wear appropriate PPE at all times: laboratory coat, chemical-resistant gloves, and safety goggles.
• Handle in a well-ventilated fume hood. Organohalide compounds may release irritating vapors; avoid inhalation.
• Consult the Safety Data Sheet (SDS) for 3-Bromo-6-fluoroimidazo[1,2-a]pyridine before use. Specific toxicological data should be verified in the SDS supplied with the product.
• Dispose of waste according to local institutional and regulatory guidelines for halogenated organic compounds.

Step-by-Step Protocol: Suzuki–Miyaura Cross-Coupling (Representative Procedure)

The following is a representative general protocol for palladium-catalyzed Suzuki–Miyaura coupling using 3-Bromo-6-fluoroimidazo[1,2-a]pyridine as the aryl bromide partner. Researchers should optimize conditions (catalyst loading, base, solvent, temperature, and time) for their specific coupling partner and scale.

1. Setup: Flame-dry a round-bottom flask under vacuum and backfill with nitrogen (or argon). Repeat three times.
2. Charge reagents: Add 3-Bromo-6-fluoroimidazo[1,2-a]pyridine (1.0 equiv), the desired boronic acid or boronate ester (1.1–1.5 equiv), Pd catalyst (e.g., Pd(PPh₃)₄ or Pd(dppf)Cl₂, 2–5 mol%), and base (e.g., K₂CO₃ or Cs₂CO₃, 2–3 equiv) to the flask.
3. Solvent addition: Add a degassed solvent mixture (e.g., DMF/H₂O 4:1, dioxane/H₂O 4:1, or toluene/EtOH/H₂O) to dissolve all solid reagents under inert atmosphere.
4. Degassing: If not already performed, degas the reaction mixture by three freeze–pump–thaw cycles or by sparging with nitrogen for 15 minutes.
5. Reaction: Heat the mixture at 80–100 °C (oil bath or microwave) with stirring for 2–16 hours, monitoring by TLC or LCMS.
6. Workup: Allow the mixture to cool to room temperature. Dilute with ethyl acetate, wash with water and brine, dry over Na₂SO₄, filter, and concentrate under reduced pressure.
7. Purification: Purify the crude product by silica gel column chromatography or preparative HPLC as appropriate.
8. Analysis: Characterize the product by ¹H NMR, ¹³C NMR, ¹⁹F NMR (if fluorine retained), and HRMS or LCMS.

Note: The C-6 fluorine is typically stable under standard Suzuki coupling conditions and is retained in the product, enabling further functionalization or serving as a pharmacophoric element in the final compound.

Storage, Handling, and Solubility Guidelines

Storage: Store 3-Bromo-6-fluoroimidazo[1,2-a]pyridine in a tightly sealed container in a cool, dry, well-ventilated area, protected from light and moisture. Extended storage under inert atmosphere (e.g., under argon) is recommended to maintain compound integrity. Keep away from incompatible materials including strong oxidizing agents and strong bases.

Solubility: Imidazo[1,2-a]pyridine derivatives are generally soluble in common polar aprotic solvents such as DMSO, DMF, and acetonitrile. Solubility in protic solvents (water, methanol, ethanol) may be limited and should be empirically determined for specific applications. For stock solution preparation, DMSO is commonly used (concentration to be determined by the user based on specific needs).

Handling Tips:

• Weigh the compound in a fume hood to minimize dust exposure.
• Allow cold storage containers to equilibrate to room temperature before opening to prevent condensation on the compound.
• Use clean, dry glassware and spatulas to avoid contamination.
• Re-seal the container immediately after use under inert gas if possible.

Troubleshooting and Quality Control

Common Issues and Solutions:

• Low coupling yield: Ensure thorough degassing of solvents and reagents. Check catalyst activity (use fresh catalyst). Increase base equivalents or switch base. Optimize temperature and reaction time. Consider switching Pd source or ligand.
• Protodebromination (loss of Br without coupling): Reduce reaction temperature. Use a milder base. Switch to a more selective catalyst/ligand system.
• Undesired C–F activation: Under standard Suzuki conditions the C–F bond is generally inert; however, if C–F activation is suspected, lower the reaction temperature and use a less reactive catalyst.
• Compound decomposition in solution: Prepare fresh solutions prior to use. Avoid prolonged storage of solutions at elevated temperatures or in protic solvents.

Quality Control Checks:

• Verify compound identity and purity by ¹H NMR and ¹⁹F NMR before use, comparing with expected spectral data for the imidazo[1,2-a]pyridine scaffold.
• Use LCMS or GC to assess purity if required by the application.
• Confirm the molecular ion by HRMS or ESI-MS.